Plus Therapeutics to Present ReSPECT Phase 1 Dose Escalation Study Results for Leptomeningeal Metastases at the 2025 San Antonio Breast Cancer Symposium

Rhea-AI Summary

Plus Therapeutics (Nasdaq: PSTV) announced acceptance of an abstract for a poster spotlight with oral presentation at the San Antonio Breast Cancer Symposium (SABCS) on Dec 12, 2025. The presentation will report Phase 1 dose-escalation results for rhenium (186Re) obisbemeda (186RNL) in patients with leptomeningeal metastases (LM).

Presenter Andrew Brenner, M.D., Ph.D., will present on Dec 12, 2025 at 7:39 AM CST in Hemisfair 3 at the Henry B. Gonzalez Convention Center. LM affects roughly 5% of metastatic cancer patients and has median survival of 2–6 months, underscoring the unmet need for new CNS-targeted therapies.

News Market Reaction

-4.44%

8 alerts

-4.44% News Effect

-$4M Valuation Impact

$80M Market Cap

0.5x Rel. Volume

On the day this news was published, PSTV declined 4.44%, reflecting a moderate negative market reaction. Our momentum scanner triggered 8 alerts that day, indicating moderate trading interest and price volatility. This price movement removed approximately $4M from the company's valuation, bringing the market cap to $80M at that time.

Data tracked by StockTitan Argus on the day of publication.

Key Figures

LM incidence: 5% LM median survival: 2–6 months SABCS dates: December 9–12, 2025 +2 more

5 metrics

LM incidence 5% Share of metastatic cancer patients developing leptomeningeal metastases

LM median survival 2–6 months Typical survival for leptomeningeal metastases patients

SABCS dates December 9–12, 2025 San Antonio Breast Cancer Symposium schedule

Presentation time 7:39–7:42 am CST Poster spotlight oral presentation window

Session time 7:00–8:30 am CST Session window for SABCS poster spotlight

Market Reality Check

Price: $0.2878 Vol: Volume 6,576,317 is sligh...

normal vol

$0.2878 Last Close

Volume Volume 6,576,317 is slightly above the 20-day average of 5,893,922. normal

Technical Price at $0.72 is trading above the 200-day MA of $0.59.

Peers on Argus

Peers show mixed moves with several small gains and declines; one related biotec...

1 Up

Peers show mixed moves with several small gains and declines; one related biotech (IPSC) appeared on a momentum scanner up 4.75%, but there is no broad, synchronized sector move corresponding to this PSTV clinical-trial headline.

Historical Context

5 past events · Latest: Dec 09 (Positive)

Pattern 5 events

Date	Event	Sentiment	Move	Catalyst
Dec 09	Business expansion	Positive	+6.3%	CNSide team expansion and inducement grants targeting CNS cancer assay growth.
Dec 04	Clinical data update	Positive	+9.8%	Three REYOBIQ LM and GBM data presentations with dose and survival details.
Dec 01	Conference presentation	Positive	-4.4%	SABCS abstract acceptance for Phase 1 LM dose-escalation results with spotlight slot.
Nov 24	Regulatory meeting	Positive	+8.0%	Constructive FDA Type B meeting on pivotal LM trial planning for REYOBIQ.
Nov 20	Reimbursement update	Positive	-0.3%	Humana national coverage for CNSide CSF assay expanding covered lives and usage.

Pattern Detected

Positive operational and clinical news has often led to upside moves, but several strong LM and diagnostics updates have seen flat or negative reactions, indicating inconsistent price responses to favorable news.

Recent Company History

Over recent months, Plus Therapeutics reported multiple CNS-focused milestones. Coverage expansion for the CNSide assay and new hires supported a large $6 billion+ addressable market. REYOBIQ clinical updates in LM and glioblastoma highlighted encouraging efficacy and safety, and an FDA Type B meeting defined a path toward a pivotal LM trial. Today’s SABCS Phase 1 LM dose-escalation presentation continues this pattern of advancing and showcasing the LM program at major oncology conferences.

Market Pulse Summary

This announcement highlights acceptance of Phase 1 ReSPECT‑LM dose‑escalation results for a poster s...

Analysis

This announcement highlights acceptance of Phase 1 ReSPECT‑LM dose‑escalation results for a poster spotlight at SABCS, reinforcing Plus Therapeutics’ focus on leptomeningeal metastases, a condition affecting about 5% of metastatic cancer patients with median survival of 2–6 months. Recent history shows a stream of LM‑focused data, diagnostics coverage wins, and an FDA meeting on a pivotal trial path. Key factors to watch include future trial design details, additional efficacy and safety data, and financing or listing‑compliance developments.

Key Terms

leptomeningeal metastases, central nervous system, radiotherapeutics, phase 1, +4 more

8 terms

leptomeningeal metastases medical

"Rhenium (186Re) obisbemeda ... for the treatment of leptomeningeal metastases (LM)"

Leptomeningeal metastases occur when cancer cells spread to the thin layers of tissue covering the brain and spinal cord, similar to how weeds can invade the surface layer of soil. This condition often indicates advanced disease and can lead to serious neurological problems. For investors, the presence of such metastases may signal challenges in treatment options and can impact the outlook for related healthcare companies or research developments.

central nervous system medical

"radiotherapeutics with advanced platform technologies for central nervous system (CNS) cancers"

The central nervous system (CNS) is the body's main control center, made up of the brain and spinal cord, that processes information and directs movement, sensation and basic functions like breathing. For investors, CNS-related products and research matter because they face long development times, strict safety testing and regulatory hurdles; success or failure can dramatically affect a company’s costs, timelines and potential market value.

radiotherapeutics medical

"a clinical-stage pharmaceutical company developing targeted radiotherapeutics with advanced platform technologies"

Radiotherapeutics are medical treatments that use tiny amounts of radioactive material to directly damage and kill diseased cells, most often cancer, by delivering radiation precisely to a tumor rather than the whole body. Investors care because these products combine drug development, specialized manufacturing and strict regulation—so clinical trial results, approval decisions, supply reliability and reimbursement determine commercial potential much like a new, precision tool transforming how a common problem is fixed.

phase 1 medical

"Phase 1 dose escalation study results"

Phase 1 is the first stage of testing a new drug or medical treatment in people, focused primarily on safety, how the body handles the product, and finding a tolerated dose. Think of it as a short, tightly controlled experiment with a small group to check for dangerous side effects before wider testing; for investors it is an early milestone that reduces some uncertainty but still carries high risk and potential for both big value changes and setbacks.

dose escalation medical

"Phase 1 dose escalation study results"

Dose escalation is the process of gradually increasing the amount of a treatment or substance over time. In finance, it can refer to slowly raising investments or commitments to manage risk and assess performance. For investors, understanding dose escalation helps gauge how companies or strategies adjust their approaches, which can impact future growth or stability.

poster spotlight technical

"acceptance of an abstract for poster spotlight (with oral) presentation"

A poster spotlight is a highlighted presentation at a scientific or medical conference where a single research poster is given extra attention—often a brief, focused talk or featured display—to draw attendees to important data or findings. For investors, a poster spotlight can act like a preview or quality marker: it signals that researchers or peers consider the data notable, which may influence perceptions of a therapy’s progress, credibility, or commercial potential.

metastatic cancer medical

"LM occurs in approximately 5% of patients with metastatic cancer"

Metastatic cancer is cancer that has spread from its original site to other parts of the body, like seeds carried from one garden bed to take root in another. It matters to investors because cancers that have spread are usually harder to treat, require more complex and expensive therapies, and drive greater demand for novel drugs, diagnostic tools, and long-term care — all of which can strongly affect the commercial prospects and regulatory risk for healthcare companies.

median survival medical

"Median survival is typically 2-6 months"

Median survival is the amount of time from a defined starting point (like diagnosis or treatment) at which half of a group of patients are still alive and half have died. Investors use it to judge how much a medical treatment or clinical result changes patient outcomes — like measuring the midpoint in a race rather than the average finish time — which affects regulatory approval chances, market size, pricing power, and revenue forecasts.

AI-generated analysis. Not financial advice.

Study findings to be featured in a poster spotlight presentation

HOUSTON, Dec. 01, 2025 (GLOBE NEWSWIRE) -- Plus Therapeutics, Inc. (Nasdaq: PSTV) (the “Company”), a clinical-stage pharmaceutical company developing targeted radiotherapeutics with advanced platform technologies for central nervous system (CNS) cancers, announces the acceptance of an abstract for poster spotlight (with oral) presentation at the upcoming San Antonio Breast Cancer Symposium (SABCS), being held on December 9-12, 2025, in San Antonio, TX.

Poster Spotlight Presentation:
Title	Rhenium (186Re) obisbemeda (rhenium nanoliposome, 186RNL) for the treatment of leptomeningeal metastases (LM): Phase 1 dose escalation study results
Presenter	Andrew Brenner, M.D., Ph.D., Professor and Kolitz / Zachry Endowed Chair Neuro-Oncology Research; Co-Leader, Experimental and Developmental Therapeutics Program, University of Texas Health, Science Center at San Antonio
Presentation
Date/Time	Friday, December 12, 2025, 7:39am to 7:42 am CST
Session
Date/Time	Friday, December 12, 2025, 7:00am to 8:30 am CST
Location	Hemisfair 3, Henry B. Gonzalez Convention Center

About LM
Leptomeningeal metastases (LM) are a rare but severe complication of advanced cancer, affecting the fluid-lined structures of the central nervous system. LM occurs in approximately 5% of patients with metastatic cancer, with breast cancer, lung cancer, and melanoma being the most common sources. Median survival is typically 2-6 months, and effective treatment options are limited, highlighting the urgent need for novel therapies.

About REYOBIQ™ (rhenium Re186 obisbemeda)
REYOBIQ (rhenium Re186 obisbemeda) is a novel injectable radiotherapy specifically formulated to deliver direct targeted high dose radiation in CNS tumors in a safe, effective, and convenient manner to optimize patient outcomes. REYOBIQ has the potential to reduce off target risks and improve outcomes for CNS cancer patients, versus currently approved therapies, with a more targeted and potent radiation dose. Rhenium-186 is an ideal radioisotope for CNS therapeutic applications due to its short half-life, beta energy for destroying cancerous tissue, and gamma energy for real-time imaging. REYOBIQ is being evaluated for the treatment of recurrent glioblastoma, leptomeningeal metastases, and pediatric brain cancer in the ReSPECT-GBM, ReSPECT-LM, and ReSPECT-PBC clinical trials. ReSPECT-GBM is supported by an award from the National Cancer Institute (NCI), part of the U.S. National Institutes of Health (NIH), and ReSPECT-LM is funded by a three-year $17.6M grant by the Cancer Prevention & Research Institute of Texas (CPRIT). The Company’s ReSPECT-PBC clinical trial for pediatric brain cancer is supported by a $3 million grant from the U.S. Department of Defense’s Peer Reviewed Cancer Research Program.

About CNSide Diagnostic, LLC
CNSide Diagnostics, LLC is a wholly owned subsidiary of Plus Therapeutics, Inc. that develops and commercializes proprietary laboratory-developed tests, such as CNSide^®, designed to identify tumor cells that have metastasized to the central nervous system in patients with carcinomas and melanomas. The CNSide^® CSF Assay Platform enables quantitative analysis of the cerebrospinal fluid that informs and improves the management of patients with leptomeningeal metastases.

About Plus Therapeutics
Headquartered in Houston, Texas, Plus Therapeutics, Inc. is a clinical-stage pharmaceutical company developing targeted radiotherapeutics for difficult-to-treat cancers of the central nervous system with the potential to enhance clinical outcomes. Combining image-guided local beta radiation and targeted drug delivery approaches, the Company is advancing a pipeline of product candidates with lead programs in leptomeningeal metastases (LM) and recurrent glioblastoma (GBM). The Company has built a supply chain through strategic partnerships that enable the development, manufacturing, and future potential commercialization of its products. For more information, visit https://www.plustherapeutics.com.

Forward-Looking Statements
This press release contains statements that may be deemed “forward-looking statements” within the meaning of U.S. securities laws, including statements regarding clinical trials, expected operations and upcoming developments. All statements in this press release other than statements of historical fact are forward-looking statements. These forward-looking statements may be identified by future verbs, as well as terms such as “expect” “potential,” “anticipating,” “planning” and similar expressions or the negatives thereof. Such statements are based upon certain assumptions and assessments made by management in light of their experience and their perception of historical trends, current conditions, expected future developments and other factors they believe to be appropriate.

The forward-looking statements included in this press release could differ materially from those expressed or implied by these forward-looking statements because of risks, uncertainties, and other factors that include, but are not limited to, the following: the Company’s ability to maintain the listing of its common stock on Nasdaq; risks related to a halt in trading or delisting of the Company’s common stock on Nasdaq; Medicare and private payors may not provide coverage and reimbursement or may breach, rescind or modify their contracts or reimbursement policies or delay payments; the risk that our products and services may not perform as expected; the early stage of the Company’s product candidates and therapies; the results of the Company’s research and development activities, including uncertainties relating to the clinical trials of its product candidates and therapies; the Company’s liquidity and capital resources and its ability to raise additional cash; the outcome of the Company’s partnering/licensing efforts, risks associated with laws or regulatory requirements applicable to it; market conditions, product performance, litigation or potential litigation, and competition within the cancer diagnostics and therapeutics field; ability to develop and protect proprietary intellectual property or obtain licenses to intellectual property developed by others on commercially reasonable and competitive terms; challenges associated with radiotherapeutic manufacturing, production and distribution capabilities necessary to support the Company’s clinical trials and any commercial level product demand; and material security breach or cybersecurity attack affecting the Company’s operations or property. This list of risks, uncertainties, and other factors is not complete. Plus Therapeutics discusses some of these matters more fully, as well as certain risk factors that could affect Plus Therapeutics’ business, financial condition, results of operations, and prospects, in its reports filed with the SEC, including Plus Therapeutics’ annual report on Form 10-K for the fiscal year ended December 31, 2024, quarterly reports on Form 10-Q, and current reports on Form 8-K. These filings are available for review through the SEC’s website at www.sec.gov. Any or all forward-looking statements Plus Therapeutics makes may turn out to be wrong and can be affected by inaccurate assumptions Plus Therapeutics might make or by known or unknown risks, uncertainties, and other factors, including those identified in this press release. Accordingly, you should not place undue reliance on the forward-looking statements made in this press release, which speak only as of its date. The Company assumes no responsibility to update or revise any forward-looking statements to reflect events, trends or circumstances after the date they are made unless the Company has an obligation under U.S. federal securities laws to do so.

Investor Contact
CORE IR
investor@plustherapeutics.com

FAQ

When will Plus Therapeutics (PSTV) present the 186RNL Phase 1 LM results at SABCS 2025?

Plus Therapeutics will present on December 12, 2025 at 7:39 AM CST during the poster spotlight session.

Who is presenting the PSTV 186RNL leptomeningeal metastases data at SABCS?

The data will be presented by Andrew Brenner, M.D., Ph.D., Professor and Kolitz/Zachry Endowed Chair Neuro-Oncology Research.

What therapy is Plus Therapeutics (PSTV) reporting for leptomeningeal metastases at SABCS?

The presentation covers rhenium (186Re) obisbemeda (186RNL), a rhenium nanoliposome radiotherapeutic evaluated in a Phase 1 dose-escalation study.

What are the clinical implications of the PSTV SABCS poster for investors?

The poster presents Phase 1 dose-escalation results for a CNS-targeted therapy addressing a high-unmet-need condition with limited treatment options.

Where can investors attend the Plus Therapeutics SABCS presentation for PSTV 186RNL data?

The presentation will be held in Hemisfair 3, Henry B. Gonzalez Convention Center during the SABCS session on December 12, 2025.